Literature DB >> 2510362

Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemofil M).

D Piszkiewicz1, C S Sun, S C Tondreau.   

Abstract

Cold supernatant which was prepared from factor VIII:C containing cryoprecipitate was seeded with HIV-1, then treated with a mixture of tri (n-butyl) phosphate (TNBP) and triton X-100. A greater than 10(11)-fold reduction of HIV-1 infectivity was observed. In a separate experiment, cold supernatant which had been seeded with HIV-1 was chromatographed on an immunoaffinity column, resulting in a 10(4)-fold reduction of infectivity. None of the 17 patients treated with the purified product and followed for at least three months has shown serologic evidence of HIV-1 or other viral infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510362     DOI: 10.1016/0049-3848(89)90395-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Extracting, storing, and transporting whole blood DNA under tropical conditions.

Authors:  I Bates; G Bedu-Addo; T R Rutherford
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

Review 2.  Ultrapure plasma factor VIII produced by anti-F VIII c immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic factor (human).

Authors:  M Griffith
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

Review 3.  Blood protein derivative viral safety: observations and analysis.

Authors:  B Horowitz
Journal:  Yale J Biol Med       Date:  1990 Sep-Oct
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.